Neoplasms, Germ Cell and Embryonal × Thoracic × Clear all
NCT03093116 2025-07-10

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 5 FDA
NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Deciphera Pharmaceuticals, LLC

Phase 1 Completed
282 enrolled
NCT02859415 2022-04-05

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 10 charts
NCT04697446 2021-08-10

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Blueprint Medicines Corporation

Unknown
279 enrolled
NCT00753415 2015-03-17

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Merck Sharp & Dohme LLC

Phase 1 Completed
37 enrolled 10 charts